NICE Technology Appraisal Guidance No 79 - Newer drugs for
epilepsy in children
Appraisal Guidance No 79 - Newer drugs for epilepsy in
NHSScotland should note NICE Technology Appraisal Guidance Nos.
77, 78 and 79 that:
No important differences were identified for these NICE Guidance
reports, and NHS Quality Improvement Scotland advises that they are
as valid for Scotland as for England and Wales.
NHSScotland should take account of this NICE Guidance and NHS
Quality Improvement Scotland email in its planning, funding and
provision of services to ensure that recommended drugs or
treatments are made available to meet clinical need.
NHS Quality Improvement Scotland advice represents the
evidence-based view of NHS Quality Improvement Scotland.
This advice does not override or replace the individual
responsibility of health professionals to make appropriate
decisions in the circumstances of their individual patients, in
consultation with the patient and/or guardian or carer.
No other publication on the NICE Guidance will be issued by NHS
Quality Improvement Scotland.
Copies of the NICE Guidance are attached for your information.
They include a section on "implications for the NHS" which you may
find helpful in assessing the likely impact of the health
technology locally. Additionally, an easy to read summary of the
guidance, called 'understanding NICE guidance" is published on the
NICE website to provide information for patients and the
While this email alert is distributed widely in NHSScotland, I
would appreciate if Board Medical Directors could forward this
email to relevant health professionals in their Board.
Hard copies of the NICE Guidance are available from NHS Quality
Improvement Scotland (contact Shonagh Buchanan, tel 0141 225 6993
Published Date: 21 April 2004